Cancer drug setback tarnishes AstraZeneca's R&D claims By: Reuters: Company News June 26, 2014 at 06:31 AM EDT * U.S. experts vote against accelerated approval of olaparib Read More >> Related Stocks: AbbVie Astrazeneca Plc ADR Clovis Oncology Inc Pfizer Tesaro Inc